RealVNC mid banner careers
ARM Innovation Hub
Advertisement EY mid banner
Advertisement: Bradfield Centre mid
RealVNC mid-banner general
Barr Ellison Solicitors – commercial property
Advertisement: RSM
Advertisement: Cambridge Network
Advertisement Cambridge China Centre
Advertisement: Mogrify
Mid banner advertisement: BDO
13 July, 2006 - 17:36 By Staff Reporter

Industry award for Cambridge biotech

Domantis, the human Domain Antibody (dAb) therapeutics company based in Cambridge, is the first winner of the UK Innovation in Drug Discovery & Development Award - one of three new BioEntrepreneur Awards sponsored by London First and UK Trade & Investment.

Domantis, the human Domain Antibody (dAb) therapeutics company based in Cambridge, is the first winner of the UK Innovation in Drug Discovery & Development Award - one of three new BioEntrepreneur Awards sponsored by London First and UK Trade & Investment.

The award recognises the contribution Domantis has made to the UK?s dominant position in the development of innovative medicine and was announced by Andrew Cahn, chief executive of UK Trade & Investment, at an awards ceremony at the Foreign and Commonwealth Office.

Domantis executive VP and chief scientific officer Dr Ian Tomlinson said: ?The award highlights Domantis? pioneering approach to developing novel therapeutics based on human Domain Antibodies.

?Domantis is fortunate to have a team of world-class scientists at its Cambridge facility and they are currently building a rich pipeline of novel dAb medicines to combat disorders such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis (RA) and cancer. "It's a tribute to their skills and creativity that we should be the first recipients of this prestigious award and this is a particularly gratifying outcome, given the high quality of the competition."

dAbs are the smallest functional binding units of human antibodies (IgG). Their natural stability and solubility coupled with their small size means that they can be used more widely in medicine compared with conventional IgGs. Domantis is using dAbs to build therapies that are not possible with IgGs, including dual targeting products, therapeutics targeting cell-surface receptors and dAb drugs delivered to targets in the lung via pulmonary administration.

The UK BioEntrepreneur of the Year Awards seek to recognise the best and newest innovators in the UK biotechnology sector.

The two other finalists in contention for the UK Innovation in Drug Discovery & Development Award were Powdermed and Spirogen.

 

 

Add new comment

Newsletter Subscription

Stay informed of the latest news and features